GentleWave System for Apical Periodontitis
Trial Summary
What is the purpose of this trial?
The purpose of this 12-month prospective cohort study is to evaluate post-operatory pain, patient satisfaction, and treatment outcomes (i.e., healing) when the newly-developed, 510k FDA-approved multisonic energy GentleWAve System (Sonendo, Inc., Laguna Hills, CA) is used in complex root canal procedures.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it does exclude people taking corticosteroids.
What data supports the effectiveness of the GentleWave System treatment for apical periodontitis?
Is the GentleWave System safe for use in humans?
How does the GentleWave System treatment differ from other treatments for apical periodontitis?
Research Team
Fabricio Teixeira, DDS,MS,PhD
Principal Investigator
University of Iowa College of Dentistry
Eligibility Criteria
This trial is for adults over 18 who can read and speak English, have specific types of molars with a diagnosis of pulp necrosis and apical periodontitis, and can attend follow-ups. It's not for those with untreated gum disease, poor dental visit attendance, or students/trainees linked to the research team.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive root canal therapy using the Sonendo GentleWave System
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- GentleWave System
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Iowa
Lead Sponsor